SEC Tracker
Get the app

Pluri PLUR

Pluri FY 2023: revenue $287K, up 23%; diluted EPS −$0.78

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Pluri reported for the year ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$287K+23% from $234K in FY 202210-K income statement, on EDGAR
  2. Net income−$28.3MAgainst −$41.2M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$0.78Against −$1.28 in FY 202210-K income statement, on EDGAR
  4. Cash and cash equivalents$5.4M−45% from $9.8M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$22.9MAgainst −$36.5M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Pluri files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  4. CalciMedica CALC public float $16M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025